MPNST
MCID: MLG077
MIFTS: 62

Malignant Peripheral Nerve Sheath Tumor (MPNST)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor 11 19 58 14 16 71 75
Malignant Neurilemmoma 19 58 53
Neurofibrosarcoma 19 58 71
Mpnst 19 58 53
Malignant Neurofibroma 19 58
Malignant Schwannoma 19 58
Neurogenic Sarcoma 19 58
Malignant Neoplasm of the Peripheral Nerve Sheath 11
Malignant Peripheral Nerve Sheath Tumors 53
Schwannoma, Malignant 75

Characteristics:


Prevelance:

1-9/100000 (Worldwide) 58

Age Of Onset:

Adolescent,Adult,Childhood,Elderly,Infancy 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:5940
MeSH 43 D018319
NCIt 49 C3798
SNOMED-CT 68 134324009
ICD10 via Orphanet 32 C47.9
UMLS via Orphanet 72 C0206729 C0751690
Orphanet 58 ORPHA3148
UMLS 71 C0206729 C0751690

Summaries for Malignant Peripheral Nerve Sheath Tumor

GARD: 19 A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.

MalaCards based summary: Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to malignant triton tumor and epithelioid malignant peripheral nerve sheath tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and Disease. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and small intestine, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Orphanet: 58 Malignant peripheral nerve sheath tumor (MPNST) is a rare and often aggressive soft tissue sarcoma occurring in a wide range of anatomical sites.

Wikipedia 75 Malignant peripheral nerve sheath tumor: A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue... more...

Schwannoma, malignant: A neurofibroma is a benign nerve-sheath tumor in the peripheral nervous system. In 90% of cases, they... more...

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Diseases in the Benign Peripheral Nerve Sheath Tumor family:

Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 724)
# Related Disease Score Top Affiliating Genes
1 malignant triton tumor 33.2 SOX10 NF1 MYOG CD34
2 epithelioid malignant peripheral nerve sheath tumor 33.1 SOX10 NF1 MYOG CD34
3 malignant glandular tumor of peripheral nerve sheath 32.8 SOX10 NF1 MYOG
4 neurofibrosarcoma 32.7 TP53 SOX10 NF2 NF1 KIT CDKN2A
5 lipofibromatosis-like neural tumor 32.4 SOX10 CD34
6 neurofibromatosis 32.2 TP53 PDGFRA NF2 NF1 KIT EGFR
7 neurofibromatosis, type i 31.7 TP53 S100B PDGFRA NF2 NF1 KIT
8 acoustic neuroma 31.5 NF2 NF1 CD44
9 sarcoma 31.3 VIM TP53 S100B S100A1 PDGFRA MYOG
10 neurilemmoma 31.2 VIM SOX10 S100B S100A1 PDGFRA NF2
11 orbital cancer 31.1 NF2 NF1 CD34
12 neurofibroma 31.1 VIM TP53 SOX10 S100B S100A1 PDGFRA
13 lung benign neoplasm 31.1 TP53 MET EGFR CDKN2A
14 fibrosarcoma 31.1 VIM TP53 PDGFRA KIT EGFR ACTC1
15 connective tissue benign neoplasm 31.0 TP53 SOX10 NF1 MDM2 KIT CD34
16 pheochromocytoma 31.0 VIM S100B NF1 KIT CDKN2A CD44
17 cellular schwannoma 31.0 SOX10 NF2 NF1 KIT CD34
18 mesothelioma, malignant 31.0 VIM NF2 MET CDKN2A
19 rhabdoid cancer 31.0 VIM TP53 ACTC1
20 ocular melanoma 31.0 NF1 KIT CDKN2A
21 skin benign neoplasm 31.0 TP53 NF1 CD34
22 neurilemmomatosis 31.0 SOX10 NF2 NF1 CDKN2A
23 malignant spindle cell melanoma 30.9 TP53 SOX10 NF1 KIT CDKN2A CD34
24 epidural spinal canal neoplasm 30.9 NF2 NF1 CD34
25 plexiform neurofibroma 30.9 TP53 SOX10 S100B PDGFRA NF2 NF1
26 perineurioma 30.9 VIM S100B NF2 KIT CD34 ACTC1
27 monophasic synovial sarcoma 30.9 SOX10 MYOG CD34
28 atypical neurofibroma 30.9 TP53 SOX10 NF2 NF1 CDKN2A
29 fibrous histiocytoma 30.8 VIM SOX10 S100B CD34 ACTC1
30 bap1 tumor predisposition syndrome 30.8 TP53 NF2 NF1 MET KIT EGFR
31 peritoneal mesothelioma 30.8 TP53 NF2 CDKN2A
32 sarcoma, synovial 30.8 VIM S100B NF1 MYOG MET MDM2
33 penile cancer 30.8 TP53 EGFR CDKN2A
34 cholecystitis 30.8 TP53 EGFR CDKN2A
35 carney complex variant 30.7 TP53 NF2 NF1
36 angiosarcoma 30.7 VIM PDGFRA MDM2 KIT CD34 ACTC1
37 cutaneous fibrous histiocytoma 30.7 SOX10 S100B S100A1 CD34 ACTC1
38 plexiform schwannoma 30.7 SOX10 NF2 NF1 KIT CD34
39 neurilemmoma of the fifth cranial nerve 30.7 NF2 NF1 CD34
40 vulva cancer 30.7 TP53 KIT EGFR CDKN2A
41 laryngeal benign neoplasm 30.7 TP53 EGFR CDKN2A CD44
42 blastoma 30.7 TP53 S100B MYOG KIT EGFR
43 mesenchymal cell neoplasm 30.7 TP53 PDGFRA NF1 MYOG MDM2 KIT
44 granular cell tumor 30.7 VIM S100B S100A1
45 thymoma 30.7 TP53 KIT EGFR CDKN2A
46 sarcomatoid squamous cell skin carcinoma 30.6 SOX10 MYOG CD34
47 b-lymphoblastic leukemia/lymphoma 30.6 KIT CDKN2A CD34
48 diffuse astrocytoma 30.6 TP53 PDGFRA NF1 EGFR CDKN2A
49 prostate sarcoma 30.6 MYOG CD34
50 cowden syndrome 30.6 TP53 NF2 NF1 EGFR CDKN2A

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:



Diseases related to Malignant Peripheral Nerve Sheath Tumor

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

25 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.45 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.45 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.45 MET
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.45 SOX10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.45 MET
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.45 EGFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.45 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.45 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.45 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.45 SOX10 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.45 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.45 MET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.45 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.45 MET
15 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.45 MET
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.45 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.45 S100B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.45 EGFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.45 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.45 MET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.45 MET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.45 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.45 S100B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.45 SOX10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.45 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.45 MET VIM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.45 S100B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.45 MET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.45 SOX10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.45 EGFR KIT MET SOX10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.45 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.45 EGFR SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.45 KIT
34 Decreased viability GR00055-A-1 10.32 EGFR
35 Decreased viability GR00055-A-2 10.32 EGFR
36 Decreased viability GR00173-A 10.32 PDGFRA
37 Decreased viability GR00221-A-1 10.32 CDKN2A EGFR KIT NF1 PDGFRA
38 Decreased viability GR00221-A-2 10.32 NF1
39 Decreased viability GR00221-A-3 10.32 CDKN2A PDGFRA
40 Decreased viability GR00221-A-4 10.32 CDKN2A EGFR NF1 PDGFRA
41 Decreased viability GR00249-S 10.32 NF1 PDGFRA
42 Decreased viability GR00301-A 10.32 KIT
43 Decreased viability GR00386-A-1 10.32 NF1
44 Decreased viability GR00402-S-2 10.32 PDGFRA
45 no effect GR00402-S-1 10.18 ACTC1 CD34 CDKN2A EGFR KIT MDM2
46 no effect GR00402-S-2 10.18 ACTC1 CD34 CD44 CDKN2A EGFR KIT
47 Reduced mammosphere formation GR00396-S 9.5 CD34 CD44 EGFR MDM2 MMP13 TOP2A
48 Increased cell migration GR00055-A-1 9.26 NF1
49 Increased cell migration GR00055-A-3 9.26 NF1

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.57 ACTC1 CD34 CD44 CDKN2A EGFR KIT
2 normal MP:0002873 10.46 ACTC1 CD44 EGFR KIT MDM2 MET
3 growth/size/body region MP:0005378 10.46 ACTC1 CD44 CDKN2A EGFR KIT MDM2
4 nervous system MP:0003631 10.45 ACTC1 CD44 CDKN2A EGFR KIT MDM2
5 muscle MP:0005369 10.44 ACTC1 CD44 CDKN2A EGFR KIT MDM2
6 cellular MP:0005384 10.42 ACTC1 CD34 CD44 CDKN2A EGFR KIT
7 neoplasm MP:0002006 10.4 CD34 CD44 CDKN2A EGFR KIT MDM2
8 endocrine/exocrine gland MP:0005379 10.36 CD44 CDKN2A EGFR KIT MDM2 MET
9 behavior/neurological MP:0005386 10.36 ACTC1 CD44 CDKN2A KIT MDM2 MET
10 embryo MP:0005380 10.35 CDKN2A EGFR KIT MDM2 MET MYOG
11 pigmentation MP:0001186 10.33 CD44 CDKN2A EGFR KIT MDM2 NF1
12 cardiovascular system MP:0005385 10.32 ACTC1 CD44 CDKN2A EGFR KIT MDM2
13 renal/urinary system MP:0005367 10.3 CD44 EGFR KIT MDM2 MET NF1
14 liver/biliary system MP:0005370 10.28 CD44 CDKN2A EGFR KIT MDM2 MET
15 limbs/digits/tail MP:0005371 10.27 CD44 EGFR KIT MDM2 MET MMP13
16 no phenotypic analysis MP:0003012 10.26 CDKN2A EGFR KIT MDM2 MET MYOG
17 digestive/alimentary MP:0005381 10.26 CD44 CDKN2A EGFR KIT MDM2 MET
18 immune system MP:0005387 10.25 CD34 CD44 CDKN2A EGFR KIT MDM2
19 respiratory system MP:0005388 10.25 CD44 CDKN2A EGFR KIT MET MYOG
20 reproductive system MP:0005389 10.15 CD44 CDKN2A EGFR KIT MDM2 NF1
21 craniofacial MP:0005382 10.11 EGFR KIT MDM2 MET NF1 NF2
22 skeleton MP:0005390 10.06 CD44 CDKN2A EGFR KIT MDM2 MMP13
23 vision/eye MP:0005391 10 CD44 CDKN2A EGFR KIT MET NF1
24 hematopoietic system MP:0005397 9.93 ACTC1 CD34 CD44 CDKN2A EGFR KIT
25 mortality/aging MP:0010768 9.86 ACTC1 CD44 CDKN2A EGFR KIT MDM2
26 integument MP:0010771 9.53 CD34 CD44 CDKN2A EGFR KIT MDM2

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
4
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
5
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
6
Palifosfamide Investigational Phase 2, Phase 3 31645-39-3 100427
7 Anti-Bacterial Agents Phase 2, Phase 3
8 Antibiotics, Antitubercular Phase 2, Phase 3
9 Liposomal doxorubicin Phase 2, Phase 3
10 Alkylating Agents Phase 2, Phase 3
11 Antineoplastic Agents, Alkylating Phase 2, Phase 3
12 Protein Kinase Inhibitors Phase 2, Phase 3
13
Imatinib Mesylate Phase 2, Phase 3 220127-57-1
14
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
16
Dacarbazine Approved, Investigational Phase 2 4342-03-4 2942 5351166
17
Adenosine Approved, Investigational Phase 2 58-61-7 60961
18
Trastuzumab Approved, Investigational Phase 2 180288-69-1
19
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
20
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
21
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
22
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
23
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
24
Lenograstim Approved, Investigational Phase 2 135968-09-1
25
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
26
Melphalan Approved Phase 2 148-82-3 4053 460612
27
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
28
Etoposide Approved Phase 2 33419-42-0 36462
29
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
30
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
31
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
32
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
33
Nivolumab Approved Phase 2 946414-94-4
34
Ipilimumab Approved Phase 2 477202-00-9
35
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
36
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6 8519
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
39
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
40
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Gemcitabine Approved Phase 1, Phase 2 95058-81-4, 122111-03-9 60750
43
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
44
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
45
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
46
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
47
D-Threonine Approved, Experimental, Nutraceutical Phase 2 72-19-5, 632-20-2 205 6288
48
Lorvotuzumab mertansine Investigational Phase 2 1008106-64-6
49
Ado-Trastuzumab Emtansine Phase 2
50
Maytansine Phase 2

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
3 An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
4 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
5 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
6 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
7 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Completed NCT02452554 Phase 2
8 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
9 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
10 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
11 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
12 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
13 A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
14 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
15 Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
16 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
17 U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II Completed NCT00068367 Phase 2 erlotinib hydrochloride
18 A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors Recruiting NCT04530487 Phase 2 Cyclosporine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus;Thiotepa
19 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
20 A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST) Recruiting NCT04872543 Phase 2 ASTX727
21 Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
22 A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion Recruiting NCT05245500 Phase 1, Phase 2 MRTX1719
23 A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors Recruiting NCT03611868 Phase 1, Phase 2 APG-115+Pembrolizumab
24 Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST) Recruiting NCT04917042 Phase 2 Tazemetostat
25 Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors) Recruiting NCT05011019 Phase 1, Phase 2 AL2846 capsules
26 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
27 A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors Active, not recruiting NCT03872427 Phase 2 Telaglenastat Hydrochloride
28 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
29 SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
30 A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors Not yet recruiting NCT05642455 Phase 1, Phase 2
31 A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112) Not yet recruiting NCT05253131 Phase 2 Selumetinib
32 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Terminated NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
33 A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
34 A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Terminated NCT02691026 Phase 2 Pembrolizumab
35 A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
36 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
37 A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors Completed NCT00931931 Phase 1
38 Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis Completed NCT02211768 Phase 1 [18F]-FLT-PET/CT scans
39 A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy Completed NCT00004853 Phase 1
40 Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor Recruiting NCT02700230 Phase 1
41 First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Recruiting NCT04222413 Phase 1 Metarrestin
42 A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas Recruiting NCT04811196 Phase 1 Selinexor
43 Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Recruiting NCT04465643 Phase 1 Nivolumab;Ipilimumab
44 Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT04483778 Phase 1
45 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Recruiting NCT04897321 Phase 1 Fludarabine;Cyclophosphamide;MESNA;B7-H3 CAR T cells
46 Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
47 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin Hydrochloride;Ribociclib
48 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Active, not recruiting NCT04420975 Phase 1
49 A Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors) Not yet recruiting NCT05107037 Phase 1 TQ-B3234 capsule
50 A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma Withdrawn NCT03880123 Phase 1 Selinexor;Ixazomib

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

Organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

MalaCards : Lung, T Cells, Small Intestine, Spinal Cord, Lymph Node, Breast, Bone

Publications for Malignant Peripheral Nerve Sheath Tumor

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 3747)
# Title Authors PMID Year
1
Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. 53 62
20399579 2010
2
The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. 53 62
20124472 2010
3
Tyrosine kinase expression in pulmonary metastases and paired primary tumors. 53 62
19948538 2010
4
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. 53 62
19634141 2010
5
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2. 53 62
19921253 2009
6
Malignant peripheral nerve sheath tumor of the uterine cervix expressing both S-100 protein and HMB-45. 53 62
20025639 2009
7
Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. 53 62
19306381 2009
8
Expression and significance of EGFR in malignant peripheral nerve sheath tumor. 53 62
19330289 2009
9
Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. 53 62
19470767 2009
10
Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. 53 62
19414372 2009
11
Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors. 53 62
19154261 2009
12
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. 53 62
18650488 2008
13
Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays. 53 62
18201235 2008
14
Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. 53 62
18547346 2008
15
Immunohistochemical study of GLUT-1 in oral peripheral nerve sheath tumors. 53 62
18826382 2008
16
Sox10: a pan-schwannian and melanocytic marker. 53 62
18636017 2008
17
Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. 53 62
18480004 2008
18
DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. 53 62
18522746 2008
19
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. 53 62
18448562 2008
20
Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. 53 62
18069666 2008
21
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. 53 62
18281533 2008
22
Malignant peripheral nerve sheath tumor of the breast: case report. 53 62
18154670 2007
23
Primary pulmonary malignant peripheral nerve sheath tumor: a case report. 53 62
17910355 2007
24
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. 53 62
17786186 2007
25
Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. 53 62
17558420 2007
26
Low grade malignant peripheral nerve sheath tumor with smooth muscle differentiation. 53 62
17119986 2007
27
Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. 53 62
17348023 2007
28
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. 53 62
17146434 2007
29
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 53 62
17300669 2007
30
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. 53 62
17235305 2007
31
Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. 53 62
17551851 2007
32
Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. 53 62
16908010 2006
33
Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. 53 62
16721726 2006
34
Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). 53 62
16818505 2006
35
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. 53 62
16528378 2006
36
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. 53 62
16510576 2006
37
Calretinin expression in tumors of adipose tissue. 53 62
16613326 2006
38
Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. 53 62
16540739 2006
39
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. 53 62
16357008 2006
40
Malignant peripheral nerve sheath tumor arising from the colon in a newborn: report of a case and review of the literatures. 53 62
16481232 2006
41
c-Kit receptor expression in normal human Schwann cells and Schwann cell lines derived from neurofibromatosis type 1 tumors. 53 62
16235251 2005
42
Apolipoprotein D is down-regulated during malignant transformation of neurofibromas. 53 62
16153462 2005
43
Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. 53 62
15897877 2005
44
FNAC diagnosis of MPNST--a case report. 53 62
16761762 2005
45
ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. 53 62
15609299 2005
46
Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB. 53 62
15602756 2005
47
Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. 53 62
15715079 2005
48
[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. 53 62
15774214 2005
49
Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. 53 62
15252314 2004
50
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. 53 62
15207265 2004

Variations for Malignant Peripheral Nerve Sheath Tumor

Cosmic variations for Malignant Peripheral Nerve Sheath Tumor:

8 (show top 50) (show all 604)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143156898 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.376G>A p.E126K 17:7673767-7673767 12
2 COSM111758616 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.713G>A p.C238Y 17:7674250-7674250 12
3 COSM143384267 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.656A>C p.E219A 17:7674190-7674190 12
4 COSM105621014 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.96+1G>A p.? 17:7676381-7676381 12
5 COSM142581311 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.704T>C p.V235A 17:7673799-7673799 12
6 COSM142560073 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.542A>G p.Y181C 17:7674872-7674872 12
7 COSM106053265 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.853G>A p.E285K 17:7673767-7673767 12
8 COSM144316114 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.400G>A p.V134M 17:7675095-7675095 12
9 COSM143370705 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.542A>G p.Y181C 17:7674872-7674872 12
10 COSM121876031 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.317G>A p.C106Y 17:7674250-7674250 12
11 COSM93183674 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.713G>A p.C238Y 17:7674250-7674250 12
12 COSM144651221 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.736G>A p.E246K 17:7673767-7673767 12
13 COSM143156869 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.236G>A p.C79Y 17:7674250-7674250 12
14 COSM111780488 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.821T>C p.V274A 17:7673799-7673799 12
15 COSM105620321 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.713G>A p.C238Y 17:7674250-7674250 12
16 COSM142838860 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.833C>A p.P278H 17:7673787-7673787 12
17 COSM93185679 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.833C>A p.P278H 17:7673787-7673787 12
18 COSM112254242 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.96+1G>A p.? 17:7676381-7676381 12
19 COSM144013959 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.502C>T p.H168Y 17:7675077-7675077 12
20 COSM144033042 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.788T>C p.V263A 17:7673799-7673799 12
21 COSM122278673 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.121G>A p.V41M 17:7675095-7675095 12
22 COSM122271391 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.263A>G p.Y88C 17:7674872-7674872 12
23 COSM111762096 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.832C>G p.P278A 17:7673788-7673788 12
24 COSM143370962 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.736G>A p.E246K 17:7673767-7673767 12
25 COSM145029562 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.656A>C p.E219A 17:7674190-7674190 12
26 COSM143162941 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.40G>A p.V14M 17:7675095-7675095 12
27 COSM106053184 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.829T>G p.C277G 17:7673791-7673791 12
28 COSM143943833 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.236G>A p.C79Y 17:7674250-7674250 12
29 COSM105622587 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.782+394C>A p.? 17:7673787-7673787 12
30 COSM143159469 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.355C>G p.P119A 17:7673788-7673788 12
31 COSM143373039 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.716C>A p.P239H 17:7673787-7673787 12
32 COSM122744599 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.565A>T p.K189* 17:7673567-7673567 12
33 COSM87898343 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.829T>G p.C277G 17:7673791-7673791 12
34 COSM143370860 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.712T>G p.C238G 17:7673791-7673791 12
35 COSM87900710 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.833C>A p.P278H 17:7673787-7673787 12
36 COSM143944441 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.58C>T p.H20Y 17:7675077-7675077 12
37 COSM106053221 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.713G>A p.C238Y 17:7674250-7674250 12
38 COSM144651747 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.418C>T p.H140Y 17:7675077-7675077 12
39 COSM144013358 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.796T>G p.C266G 17:7673791-7673791 12
40 COSM143156731 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.182A>G p.Y61C 17:7674872-7674872 12
41 COSM112264430 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.961A>T p.K321* 17:7673567-7673567 12
42 COSM143963152 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.344T>C p.V115A 17:7673799-7673799 12
43 COSM145028698 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.844A>T p.K282* 17:7673567-7673567 12
44 COSM144327798 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.704T>C p.V235A 17:7673799-7673799 12
45 COSM142570943 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.844A>T p.K282* 17:7673567-7673567 12
46 COSM112256366 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.832C>G p.P278A 17:7673788-7673788 12
47 COSM112254176 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.535C>T p.H179Y 17:7675077-7675077 12
48 COSM93195964 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.773A>C p.E258A 17:7674190-7674190 12
49 COSM111771883 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.773A>C p.E258A 17:7674190-7674190 12
50 COSM145025304 TP53 soft tissue,nerve sheath,malignant peripheral nerve sheath tumour,NS c.400G>A p.V134M 17:7675095-7675095 12

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

6 (show all 45)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17387 1 142600000 147000000 Gain Malignant peripheral nerve sheath tumor
2 22132 1 165500000 170900000 Gain Malignant peripheral nerve sheath tumor
3 23047 1 170900000 176000000 Gain Malignant peripheral nerve sheath tumor
4 49109 11 102900000 112500000 Loss Malignant peripheral nerve sheath tumor
5 49995 11 112500000 121200000 Loss Malignant peripheral nerve sheath tumor
6 53584 11 31000000 36400000 Loss Malignant peripheral nerve sheath tumor
7 61507 12 1 3100000 Gain FOXM1 Malignant peripheral nerve sheath tumor
8 65742 12 21200000 26300000 Amplification SOX5 Malignant peripheral nerve sheath tumor
9 66816 12 3300000 10100000 Gain Malignant peripheral nerve sheath tumor
10 67235 12 38200000 49100000 Gain Malignant peripheral nerve sheath tumor
11 69080 12 5300000 10000000 Gain NOP2 Malignant peripheral nerve sheath tumor
12 69882 12 56428269 56432431 Gain CDK4 Malignant peripheral nerve sheath tumor
13 69960 12 56600000 71500000 Gain Malignant peripheral nerve sheath tumor
14 71535 12 71500000 86700000 Gain Malignant peripheral nerve sheath tumor
15 73254 12 92600000 109000000 Gain Malignant peripheral nerve sheath tumor
16 73259 12 92600000 96200000 Gain Malignant peripheral nerve sheath tumor
17 75380 13 19500000 25500000 Gain Malignant peripheral nerve sheath tumor
18 76637 13 34000000 55300000 Gain Malignant peripheral nerve sheath tumor
19 79536 13 73300000 77200000 Gain Malignant peripheral nerve sheath tumor
20 85488 14 47200000 67900000 Loss Malignant peripheral nerve sheath tumor
21 87451 14 73800000 107349540 Gain Malignant peripheral nerve sheath tumor
22 97234 16 1 10500000 Gain Malignant peripheral nerve sheath tumor
23 102841 16 57400000 90354753 Gain Malignant peripheral nerve sheath tumor
24 105377 16 7900000 14800000 Gain Malignant peripheral nerve sheath tumor
25 115613 17 58300000 81195210 Gain Malignant peripheral nerve sheath tumor
26 124065 19 1 13900000 Gain Malignant peripheral nerve sheath tumor
27 147242 2 61300000 68600000 Gain Malignant peripheral nerve sheath tumor
28 150135 2 96800000 114400000 Gain Malignant peripheral nerve sheath tumor
29 163892 22 32200000 44200000 Gain Malignant peripheral nerve sheath tumor
30 172609 3 184500000 198022430 Gain Malignant peripheral nerve sheath tumor
31 174546 3 2800000 16400000 Gain Malignant peripheral nerve sheath tumor
32 175421 3 39400000 54400000 Gain Malignant peripheral nerve sheath tumor
33 196162 5 159900000 180915260 Gain Malignant peripheral nerve sheath tumor
34 198008 5 18400000 23300000 Gain Malignant peripheral nerve sheath tumor
35 209673 6 27000000 57000000 Gain Malignant peripheral nerve sheath tumor
36 213890 6 52900000 70000000 Gain Malignant peripheral nerve sheath tumor
37 220382 7 13800000 43300000 Gain Malignant peripheral nerve sheath tumor
38 227906 7 72200000 86400000 Gain Malignant peripheral nerve sheath tumor
39 240607 8 52600000 146364022 Gain Malignant peripheral nerve sheath tumor
40 241476 8 6200000 36500000 Gain Malignant peripheral nerve sheath tumor
41 244863 9 1 14200000 Gain Malignant peripheral nerve sheath tumor
42 247559 9 130300000 135900000 Gain Malignant peripheral nerve sheath tumor
43 249423 9 14200000 28000000 Loss Malignant peripheral nerve sheath tumor
44 255080 9 72339785 73251640 Dramatically overexpressed,genomicallyamplified TRPM3 Malignant peripheral nerve sheath tumor
45 255774 9 84100000 102600000 Gain Malignant peripheral nerve sheath tumor

Expression for Malignant Peripheral Nerve Sheath Tumor

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Pathways for Malignant Peripheral Nerve Sheath Tumor

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 TP53 PDGFRA NRG1 MET MDM2 KIT
2
Show member pathways
13.8 TP53 S100A1 PDGFRA NRG1 NF1 MET
3
Show member pathways
13.69 CDKN2A EGFR KIT MDM2 MET MMP13
4
Show member pathways
13.67 VIM TP53 SOX10 PDGFRA NRG1 NF1
5 13.45 ACTC1 EGFR KIT MDM2 MET NF1
6
Show member pathways
13.4 TP53 PDGFRA NRG1 MET MDM2 KIT
7
Show member pathways
13.38 TP53 PDGFRA NRG1 NF2 NF1 MET
8
Show member pathways
13.36 EGFR KIT MDM2 MET NF1 NRG1
9
Show member pathways
13.02 TP53 PDGFRA NRG1 MET MDM2 KIT
10
Show member pathways
13.01 EGFR KIT MDM2 MET NRG1 PDGFRA
11
Show member pathways
12.95 TP53 PDGFRA MET MDM2 KIT EGFR
12 12.81 EGFR KIT MET NRG1 PDGFRA S100B
13
Show member pathways
12.63 EGFR KIT MET NRG1 PDGFRA TP53
14
Show member pathways
12.61 TP53 NF1 MDM2 KIT EGFR CDKN2A
15
Show member pathways
12.58 PDGFRA NRG1 MET MDM2 KIT EGFR
16 12.5 VIM TP53 TOP2A MDM2 CDKN2A
17
Show member pathways
12.48 TP53 NRG1 MDM2 EGFR
18
Show member pathways
12.43 TP53 PDGFRA MDM2 KIT EGFR
19
Show member pathways
12.4 TP53 PDGFRA MET MDM2 EGFR
20
Show member pathways
12.37 PDGFRA NRG1 MET KIT EGFR
21
Show member pathways
12.2 TP53 PDGFRA MET MDM2 EGFR
22 12.14 TP53 NF1 MDM2 EGFR
23 12.14 EGFR KIT MET NF1 PDGFRA
24 12.1 TP53 PDGFRA MET EGFR
25
Show member pathways
12.07 S100B NRG1 MDM2 EGFR
26 12.05 TP53 MET MDM2 EGFR
27 11.97 PDGFRA NRG1 MET KIT EGFR
28 11.96 KIT EGFR CDKN2A CD44
29 11.93 TP53 PDGFRA NF2 MET MDM2 KIT
30 11.91 TP53 MDM2 CDKN2A CD44
31 11.84 MYOG KIT CD44 CD34
32 11.82 TP53 TOP2A MDM2
33 11.78 KIT CD44 CD34
34 11.78 KIT CDKN2A CD34
35
Show member pathways
11.75 TP53 MDM2 CDKN2A
36 11.73 TP53 EGFR CDKN2A
37 11.65 MMP13 EGFR CD44
38 11.61 MET MDM2 CDKN2A
39
Show member pathways
11.59 TP53 TOP2A MDM2
40 11.58 TP53 MDM2 CDKN2A
41 11.55 TP53 MDM2 CDKN2A
42 11.46 PDGFRA NRG1 KIT ACTC1
43 11.45 VIM SOX10 S100B PDGFRA CD44
44
Show member pathways
11.39 PDGFRA NF2 MET KIT EGFR CD44
45 11.34 TOP2A NRG1 MDM2 CDKN2A
46 11.33 TP53 MDM2 CDKN2A
47 11.29 TP53 TOP2A EGFR
48 11.22 TP53 MDM2 EGFR CDKN2A
49 11.07 TP53 MDM2 CDKN2A
50 11.01 VIM PDGFRA NRG1 MET KIT EGFR

GO Terms for Malignant Peripheral Nerve Sheath Tumor

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.64 PDGFRA NRG1 MET KIT EGFR CD44
2 plasma membrane GO:0005887 9.64 PDGFRA NRG1 MET KIT EGFR CD44

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 10.25 TP53 NF2 MYOG MDM2 CDKN2A
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.16 PDGFRA MET KIT EGFR
3 MAPK cascade GO:0000165 10.11 NRG1 NF2 NF1 EGFR
4 hematopoietic progenitor cell differentiation GO:0002244 10.01 TP53 TOP2A PDGFRA KIT
5 neuroblast proliferation GO:0007405 10 TP53 SOX10 NF1
6 oligodendrocyte differentiation GO:0048709 9.93 NF1 NRG1 SOX10
7 peripheral nervous system development GO:0007422 9.88 SOX10 NRG1 NF1
8 negative regulation of cell-matrix adhesion GO:0001953 9.85 NF2 NF1 CDKN2A
9 cell population proliferation GO:0008283 9.83 EGFR KIT NF1 NRG1 TP53
10 cellular response to actinomycin D GO:0072717 9.81 TP53 MDM2
11 mast cell proliferation GO:0070662 9.8 NF1 KIT
12 Schwann cell proliferation GO:0014010 9.76 NF2 NF1
13 regulation of cell population proliferation GO:0042127 9.73 TP53 NF2 NF1 KIT EGFR
14 positive regulation of gene expression GO:0010628 9.73 VIM TP53 SOX10 NRG1 KIT CDKN2A
15 negative regulation of Schwann cell proliferation GO:0010626 9.63 NF1 NF2 SOX10
16 multicellular organism development GO:0007275 9.62 PDGFRA MET KIT EGFR
17 positive regulation of miRNA maturation GO:1903800 9.58 TP53 EGFR
18 positive regulation of kinase activity GO:0033674 9.28 PDGFRA MET KIT EGFR CD44

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.7 PDGFRA MET KIT EGFR
2 disordered domain specific binding GO:0097718 9.35 TP53 MDM2 CDKN2A
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.23 PDGFRA MET KIT EGFR

Sources for Malignant Peripheral Nerve Sheath Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....